CD8A and breast cancer: Intriguingly, SERDs (either fulvestrant or JD128), despite lacking a direct antitumor effect on ER-negative BC, were found to reduce the counts of MDSCs and Tregs as well as increase the infiltration of DCs and CD8 + and CD4 + T cells in 4T1 tumor-bearing mice.